These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22280221)

  • 1. Degludec: a novel basal insulin.
    Kalra S; Baruah MP; Niazi AK
    Recent Pat Endocr Metab Immune Drug Discov; 2012 Jan; 6(1):18-23. PubMed ID: 22280221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Degludec: A Novel Basal Insulin.
    Kalra S; Baruah MP; Niazi AK
    Recent Pat Endocr Metab Immune Drug Discov; 2012 Jan; ():. PubMed ID: 22280218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Acting Basal Insulins: A Review of the More Recently Approved Agents.
    Gallegos Aragon K; Elmaoued AA; Pham NT; Conklin JR; Ray GM
    Cardiol Rev; 2019; 27(5):260-266. PubMed ID: 31393288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin detemir (levemir), a new long-acting insulin.
    Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research.
    Muñoz Torres M
    Endocrinol Nutr; 2014 Mar; 61(3):153-9. PubMed ID: 23890782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basal insulin analogues in the management of diabetes mellitus: What progress have we made?
    Owens DR; Matfin G; Monnier L
    Diabetes Metab Res Rev; 2014 Feb; 30(2):104-19. PubMed ID: 24026961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
    Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
    Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin degludec. Uncertainty over cardiovascular harms.
    Prescrire Int; 2014 Jun; 23(150):149. PubMed ID: 25121146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety among second-generation and other basal insulins in adult patients with type 1 diabetes: a systematic review and network meta-analysis.
    Martin ; Zhou Y; Takagi T; Tian YS
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Oct; 394(10):2091-2101. PubMed ID: 34319421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
    Goldman J; Kapitza C; Pettus J; Heise T
    Curr Med Res Opin; 2017 Oct; 33(10):1821-1831. PubMed ID: 28537449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.
    Berard L; MacNeill G
    Can J Diabetes; 2015 Feb; 39(1):4-9. PubMed ID: 25065475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of the Clinical Efficacy and Safety of Insulin Degludec and Glargine 300 U/mL in the Treatment of Diabetes Mellitus.
    Woo VC
    Clin Ther; 2017 Aug; 39(8S2):S12-S33. PubMed ID: 28187863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes.
    Dardano A; Bianchi C; Del Prato S; Miccoli R
    Vasc Health Risk Manag; 2014; 10():465-75. PubMed ID: 25143741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin degludec: a novel basal insulin analogue.
    Goldman-Levine JD; Patel DK; Schnee DM
    Ann Pharmacother; 2013 Feb; 47(2):269-77. PubMed ID: 23386075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of insulin degludec in type 1 and type 2 diabetes based on randomized and observational trials.
    Preumont V; Buysschaert M
    Diabetes Metab; 2020 Apr; 46(2):83-88. PubMed ID: 31055056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoglycemia rates with basal insulin analogs.
    Little S; Shaw J; Home P
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S53-64. PubMed ID: 21668338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
    Peterson GE
    Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.
    Lajara R; Cengiz E; Tanenberg RJ
    Curr Med Res Opin; 2017 Jun; 33(6):1045-1055. PubMed ID: 28277867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can a new ultra-long-acting insulin analogue improve patient care? Investigating the potential role of insulin degludec.
    Robinson JD; Neumiller JJ; Campbell RK
    Drugs; 2012 Dec; 72(18):2319-25. PubMed ID: 23145524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating to target in type 2 diabetes: the BEGIN trial programme.
    Wangnoo SK; Chowdhury S; Rao PV
    J Assoc Physicians India; 2014 Jan; 62(1 Suppl):21-6. PubMed ID: 25330628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.